AUTHORS
Esraa Almutairi, MBBS, Lisa Avery2, Massimiliano Marinoni3, Anca Prica4, Danielle Rodin, MD5, Sita Bhella, MD6, Tomohiro Aoki, MD, PhD7, Christine Chen, MHPE, MD, FRCPC8, Robert Kridel, MD9, Vishal Kukreti, MD10, Abi Vijenthira, MD, MS11, Chloe Yang, MD12, Mahmood Aminilari, PhD13, David Hodgson, MD, MPH14, Badr Id Said, MD, MSc15, Woodrow Wells, MD16, Michael Crump, MD17, John Kuruvilla, MD18, Inna Y Gong, MD, PhD19
AFFILIATIONS
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 Princess Margaret Cancer Centre, Toronto, Canada
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
4 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, toronto, Ontario, Canada
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, toronto, Ontario, Canada
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, toronto, Ontario, Canada
8 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, toronto, Ontario, Canada
11 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, toronto, Ontario, Canada
12 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, toronto, Ontario, Canada
13 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
14 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
15 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
16 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
17 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, toronto, Ontario, Canada
18 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, toronto, Ontario, Canada
19 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, toronto, Ontario, Canada
ABSTRACT
Background:
Real-world comparisons of second-line (2L) versus third-line-or-later (3L+) CD19-directed chimeric antigen receptor T-cell therapy (CAR T) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) have largely focused on infused patients (pts). Comparison of outcomes by line of therapy (LoT) across the full CAR T pathway remain less well described, highlighting the need for intention-to-treat (ITT) analyses that capture pts from initial CAR T assessment through apheresis, infusion, and subsequent outcomes.
Methods:
This study included sequentially treated pts with LBCL (including HGBCL and transformed lymphoma) intended for CAR T between 2018-2025 at Princess Margaret Cancer Centre, with follow-up to July 2026. The ITT index date was date of R/R disease; pre-infusion attrition (apheresis, infusion, reasons for non-infusion) was compared between 2L and 3L+. Multivariable Cox models for PFS (time from R/R date to progression or death) and OS (time from R/R date to death from any cause) were adjusted for age, ECOG, LDH, stage, extranodal (EN), and histology, and stratified by treatment era to account for collinearity between line of therapy and calendar time created by 2L approval. Landmark analyses were performed from CAR T infusion adjusting for CAR T product.
Results:
The cohort included 324 pts intended for CAR T (59 2L, 265 3L+; median age 62 [range 20-84], 24% ≥70 years old; 65% male). 2L pts had lower LDH ≥500 U/L (17% vs 31%, p=.018), and more holding (37% vs 20%, p=.004) and bridging therapy (85% vs 71%, p=.030). No differences were observed in HGBCL (22% vs 26%), stage III/IV (67% vs 77%), ECOG ≥2 (22% vs 34%), IPI 3-5 (60% vs 57%), or EN ≥2 sites (32% vs 40%).
Apheresis was significantly more common among 2L-intended pts (57/59, 97% in 2L vs 230/265, 87% in 3L+; p=.039). Infusion rates among all intended pts were numerically higher for 2L but did not reach significance (85% vs 75%, p=.13); among pts who underwent apheresis, infusion rates did not differ significantly by line (88% vs 87%, p=.83), indicating that attrition occurred primarily at the apheresis step rather than during bridging to infusion.
Reasons for non-infusion (2L n=9, 3L+ n=66) differed: for 2L, infection/cytopenia was most common (44%), followed by progressive disease (PD, 33%) and poor ECOG (22%); for 3L+, PD predominated (50%, and 17% due to CNS PD), followed by infection/cytopenia (12%), ECOG (14%), and manufacturing failure (8%).
Median ITT follow-up was 28 months (mos) overall (95% CI 22-32): 2L 11 mos (9-13); 3L 33 mos (29-41). On univariable analysis, when compared to 2L, 3L+ was not associated with ITT PFS (HR 1.44, 95% CI 0.94-2.19, p=.09) or OS (HR 1.18, 95% CI 0.73-1.90, p=.49). In a multivariable model stratified by treatment era, ITT PFS (aHR 0.94, 95% CI 0.50-1.76) and OS (aHR 0.91, 95% CI 0.45-1.83) likewise did not differ by LoT, with consistent estimates in the contemporary-era-only sensitivity analysis (PFS HR 0.95, OS HR 0.97).
Among 251 evaluable infused patients (axi-cel 81%, tisa-cel 14%, liso-cel 5.2%), day-30 response by Lugano criteria (PET/CT) was significantly higher in 2L (ORR 96% vs 75%, p=.0018; CR 62% vs 40%, p=.02), but this difference was not sustained at 3 months (ORR 86% vs 74%, p=.15; CR 62% vs 51%, p=.29). In a landmark analysis restricted to infused patients only, PFS (aHR 1.07, 95% CI 0.51-2.26, p=.85) and OS (aHR 0.88, 95% CI 0.37-2.13, p=.78) also did not differ by LoT.
Across ITT and infused multivariable models, ECOG ≥2 (HR range 1.86-2.06), LDH ≥500 (HR range 1.72-2.06), and HGBCL (vs. DLBCL NOS; HR range 1.49-1.65) were independent predictors of inferior PFS and OS.
CRS and ICANS rates did not differ significantly by line (CRS grade ≥2 42% vs 40%, p=.8; ICANS grade ≥2 20% vs 17%, p=.6).
Conclusion
In this ITT analysis capturing pre-infusion attrition, 2L pts were significantly more likely to reach apheresis, though infusion rates among apheresed pts were similar between 2L and 3L+. After stratification by treatment era and adjustment for covariates, LoT was not significantly associated with PFS or OS, though the 2L cohort had limited follow-up. ECOG, LDH, and HGBCL histology were consistent independent predictors of inferior outcomes across analyses, suggesting that baseline disease burden and biology may be more important determinants of outcome than LoT.
DISCLOSURES
Esraa Almutairi, MBBS: No relevant conflicts of interest to declare.